J Cancer 2019; 10(25):6364-6373. doi:10.7150/jca.29779 This issue

Research Paper

MTBHsp70-exFPR1-pulsed Dendritic Cells Enhance the Immune Response against Cervical Cancer

Guangming Cao*, Ran Cui*, Chongdong Liu, Guyu Zhang, Zhenyu Zhang

Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University
*These authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Cao G, Cui R, Liu C, Zhang G, Zhang Z. MTBHsp70-exFPR1-pulsed Dendritic Cells Enhance the Immune Response against Cervical Cancer. J Cancer 2019; 10(25):6364-6373. doi:10.7150/jca.29779. Available from https://www.jcancer.org/v10p6364.htm

File import instruction


Cervical cancer is the most common malignancy of the female reproductive system. Dendritic cell (DC)-based immunological therapy is a novel treatment for this cancer. DCs are specialized antigen-presenting cells (APCs) in the human immune system, and they can activate the T cells used in tumor immunological therapy. In this study, we developed a novel immunotherapeutic peptide by linking the Mycobacterium tuberculosis (MTB) heat shock protein 70 (Hsp70) functional peptide to the extracellular domain of FPR1, a protein overexpressed in cervical cancer, to obtain an MTBHsp70-exFPR1 fusion protein. Our experiments confirmed that the MTBHsp70-exFPR1 protein could promote DC maturation and induce the secretion of IL-12p70, IL-1β, and TNF-α. The antitumor effect of human cytotoxic T lymphocytes (CTLs) activated by autologous DCs was assessed in NOG mice. These results indicate that DCs pulsed with MTBHsp70-exFPR1 can enhance antitumor immunity against cervical cancer, providing a novel immune therapeutic strategy.

Keywords: Cervical cancer, Immunotherapy, Dendritic cells, Recombinant antigen, FPR1